Biologic Agents in Crohn’s Patients Reduce CD4⁺ T Cells Activation and Are Inversely Related to Treg Cells

Table 1

Demographic, clinical, and laboratory characteristics.

	Healthy subjects	Crohn’s patients		value
		Biological	Nonbiological
Case number	28	25	16
Treatment
	None	Adalimumab (n = 21); Infliximab (n = 4)	Anti-inflammatory + immunosuppressive + corticoids (n = 5); Anti-inflammatory + immunosuppressive (n = 4); Anti-inflammatory + corticoids (n = 6); Anti-inflammatory (n = 1)
Gender (%)
Female	68%	72%	69%
Male	32%	28%	31%
Age (years)	39	36	41
Calprotectin (μg/g)	55.4: 36–107	245: 144–631	422: 89.6–1014	Healthy vs. nonbiological,; Healthy vs. biological,
MCV (mean corpuscular volume) (fl); Median: IQR	83.9: 82.13–87.1	86.8: 83.4–90.6	87.15: 85.2–91.18	Healthy vs. nonbiological,
CHCM (cellular hemoglobin concentration mean) (g/dL); Median: IQR	34.65: 34.3–34.75	34.3: 33.15–34.75	33.13: 32.5–33.65	Healthy vs. nonbiological,
RDW (red cell distribution width) (%); Median: IQR	12.6: 12.33–13.05	13.2: 12.75–13.85	13.2: 12.9–13.38	Healthy vs. biological,
Albumin (g/dL); Median: IQR	4.4: 4.2–4.575	4.2: 4–4.4	4: 3.85–4.2	Healthy vs. nonbiological,
Globulin (g/dL); Median: IQR	2.9: 2.8–3.15	3.1: 2.9–3.55	3.1: 3–3.175	Healthy vs. biological,
ASCA_IgG (U/m); Median: IQR	5.6: 2.3–9.6	15.9: 9.8–35.5	11.6: 3.4–28.7	Healthy vs. biological,
ASCA_IgA (U/m); Median: IQR	0.9: 0.5–2.2	6.4: 2.0–15.8	2.25: 1.1–3.3	Healthy vs. biological,

IQR, interquartile, Kruskal–Wallis statistics.